|1.||Parangi, Sareh: 6 articles (06/2014 - 06/2010)|
|2.||Aplin, Andrew E: 5 articles (08/2014 - 08/2010)|
|3.||Zhang, Xu Dong: 5 articles (01/2014 - 02/2011)|
|4.||Marais, Richard: 4 articles (05/2015 - 12/2009)|
|5.||Bosenberg, Marcus W: 4 articles (02/2015 - 11/2013)|
|6.||Bollag, Gideon: 4 articles (02/2015 - 02/2008)|
|7.||Sadow, Peter M: 4 articles (06/2014 - 01/2011)|
|8.||McMahon, Martin: 4 articles (04/2014 - 10/2008)|
|9.||Hersey, Peter: 4 articles (02/2013 - 02/2011)|
|10.||Nehs, Matthew A: 4 articles (02/2012 - 06/2010)|
|1.||Melanoma (Melanoma, Malignant)
06/15/2014 - "In this study, we profiled immunologic changes in the tumor microenvironment and tumor-infiltrating lymphocytes (TIL) in a B-RafV600E/Pten-driven murine model of melanoma after administration of the B-Raf(V600E) small molecule inhibitor PLX4720. "
12/01/2015 - "Proliferation inhibition of conjunctival melanoma cells by PLX 4720 depends on their B-Raf genotype. "
12/01/2015 - "Cytotoxicity, cell viability, proliferation, apoptosis rate and phosphorylation rate of ERK and Akt were analysed in three different conjunctival melanoma cell lines under the influence of the B-Raf inhibitor PLX 4720 at various concentrations. "
12/01/2015 - "B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720."
07/01/2015 - "On the other hand, long-term treatment with PLX4720 induced pERK reactivation following BRAF inhibition in A375P cells, indicating that negative feedback including Spry2 may be bypassed in BRAF mutant melanoma cells. "
04/22/2014 - "We used small-animal ultrasound imaging to monitor autochthonous tumors and showed that treatment with the selective BRAF inhibitor PLX4720 improved survival but did not lead to tumor regression or suppress signaling through the MAPK pathway. "
03/10/2015 - "One of the subtypes identified here for the first time displayed the highest and lowest expression of EGFR and ERBB3, respectively, and included BRAF-mutant tumors all intrinsically resistant to BRAFi PLX4720, as assessed by analysis of the Cancer Cell Line Encyclopedia pharmacogenomic study and by in vitro growth inhibition assays. "
06/01/2015 - "In contrast, treatment with the vemurafenib analog PLX4720 was associated with tumor relapse at >30 days. "
05/01/2015 - "In vivo, combined treatments of RT3D and PLX4720 showed significantly increased activity in BRAF mutant tumors in both immune-deficient and immune-competent models. "
05/01/2015 - "Successful PLX-4720 therapy of recurrent tumors was associated with the development of a broad spectrum of T-cell responses. "
|3.||Thyroid Neoplasms (Thyroid Cancer)
07/10/2013 - "These results reveal a novel (V600E)BRAF-induced mechanism in thyroid tumours progression and provides a rationale for using the PLX4720 inhibitor to target (V600E)BRAF signalling to effectively control progression of thyroid cancer."
01/01/2011 - "Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer."
06/08/2010 - "Testing of a patient's thyroid cancer for B-Raf(V600E) will yield important information about potential tumor aggressiveness and also allow for future use of targeted therapies with selective B-Raf(V600E) inhibitors, such as PLX4720."
07/01/2014 - "Furthermore, BRAF(V600E) inhibitor PLX4720 can significantly down-regulate CYP24A1 expression and enhance the antiproliferative effects of calcitriol in thyroid cancer cell lines. "
06/30/2014 - "Whereas PLX4720 did not induce robust apoptosis in thyroid cancer cells, combined treatment with dasatinib induced apoptosis in 4 of 6 lines. "
|4.||Neoplasm Metastasis (Metastasis)
12/15/2014 - "NK cell frequencies were significantly enhanced by PLX4720 specifically in the lungs of mice with BRAF(V600E) lung metastases. "
06/08/2010 - "Treatment of orthotopic thyroid tumors, initiated 1 week after tumor cell implantation with PLX4720, an orally available selective inhibitor of B-Raf(V600E), caused a significant tumor growth delay and decreased distant metastases, without evidence of toxicity. "
01/01/2015 - "PLX4720 also suppressed several metastasis-associated transcripts that have not been implicated as targets, effectors or potential biomarkers of oncogenic B-Raf signaling so far. "
|5.||Colorectal Neoplasms (Colorectal Cancer)
12/01/2015 - "To gain additional insights into this difference, we performed a genome-scale pooled shRNA enhancer screen in a BRAF-mutant, RAF inhibitor-resistant colorectal cancer cell line exposed to the selective RAF inhibitor PLX4720. "
12/01/2013 - "Vulnerability to proteasome inhibitors is dependent on persistent BRAF signaling, because BRAF V600E blockade by PLX4720 reversed sensitivity to carfilzomib in BRAF-mutant colorectal cancer cells. "
|1.||sorafenib (BAY 43-9006)
|3.||Glutamic Acid (Glutamate)
|4.||Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)
|9.||Adenosine Triphosphate (ATP)
|10.||Small Interfering RNA (siRNA)
|1.||Heterologous Transplantation (Xenotransplantation)